+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Continuous Infusion of Growth Hormone-Releasing Factor: Effects on Pulsatile Growth Hormone Secretion in Normal Rats


      S. Karger AG

      Rats, Growth hormone-releasing factor, Growth hormone

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Theeffects of a continuous infusion of growth hormone-releasing factor (GRF) on pulsatile growth hormone (GH) secretion were studied in conscious, freely moving rats. Male Sprague-Dawley rats were prepared with 2 indwelling venous catheters and were then housed individually for 6–16 days in isolation chambers. After this period, normal saline, 1.5 µg/h GRF or 15 µg/h GRF were continuously infused for 8 or 31 h via one of the catheters. Blood samples were drawn at ≈ 20-min intervals via the other catheter during the last 6–7 h of the infusion. Plasma GH concentrations were determined by RIA. Saline-treated animals exhibited the typical pattern of spontaneous GH pulses. The frequency of GH pulses in animals infused with either dose of GRF was not different from that of the saline-infused rats. Likewise, trough GH concentrations were similar in all three treatment groups. However, peak GH concentrations in the rats receiving the 15-µg/h GRF infusion were remarkably higher than the concentrations observed in the other two groups, regardless of the duration of the infusion. This resulted in mean GH concentrations being significantly higher (p<O.Ol) in the 15-µg/h GRF-infused rats. These results demonstrate that pituitary episodic GH secretion continues even in the presence of a continuous GRF stimulation.

          Related collections

          Author and article information

          S. Karger AG
          01 April 2008
          : 43
          : 3
          : 391-396
          Department of Health Sciences, University of Wisconsin, Milwaukee, Wisc.; and Laboratories for Neuroendocrinology, Salk Institute, San Diego, Calif., USA
          124554 Neuroendocrinology 1986;43:391–396
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article